Cefoxitin And Dextrose In Duplex Container

(Cefoxitin)

ApprovedSmall molecule

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cefoxitin And Dextrose In Duplex Container is one of 113 small molecule programs targeting Abscess. It is currently in Approved.

Indications

Total Trials

Active Trials

112

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AbscessActive, not recruiting

PyelonephritisActive, not recruiting

Cystic FibrosisActive, not recruiting

Urinary Tract InfectionActive, not recruiting

AbscessPhase 2/Phase 3

Active, not recruiting

PyelonephritisPreclinical

Active, not recruiting

Cystic FibrosisPhase 2

Active, not recruiting

Urinary Tract InfectionApproved

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Cefoxitin And Dextrose In Duplex Container

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 2

Onglyza

AstraZeneca

Preclinical

2 3

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 4

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 5

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 6

Aztreonam Lysine

Gilead

Preclinical

5 7

Capromorelin

UUniversity of Aarhus

Preclinical

1 8

Advil

KKenvue Brands

Preclinical

1 9

Tums

Otsuka

Preclinical

1 10

Feosol

AAuerbach Hematology Oncology Associates P C

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Antibiotic

NCT06860802

Q2 2030

Phase 2/3Recruiting

Abscess

NCT04310930

Q3 2031

Phase 2Not yet recruiting

Cystic Fibrosis

NCT07485010

Clinical

Trials by Indication[1]

Antibiotic1 trial

Precision Antibiotic Dosing for Appendectomy

Recruiting·UUniversity of Michigan·Phase 1·NCT06860802·46 enrolled

Major Abdominal Surgery1 trial

Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique

Completed·PPoitiers University Hospital·Phase 4·NCT02703857·12 enrolled

Abscess1 trial

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting·TThe University of Queensland·Phase 2/3·NCT04310930·300 enrolled

Urinary Tract Infection1 trial

Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

Terminated·—·Phase 4·NCT02474706·6 enrolled

Surgical Site Infections1 trial

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT03269994·967 enrolled

3 more indications

Cystic Fibrosis1 trial

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not yet recruiting·TThe University of Queensland·Phase 2·NCT07485010·300 enrolled

Antibiotic Prophylaxis1 trial

Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic Prophylaxis

Unknown status·HHospital de Santa Maria, Portugal·N/A·NCT02985086·568 enrolled

Pyelonephritis1 trial

Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli

Terminated·AAssistance Publique - Hôpitaux de Paris·N/A·NCT01820793·9 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

MEFOXIN

NDA NDA050517

Sep 20, 1984

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

NDA NDA050581

Mar 10, 2006

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

NDA NDA065214

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Cefoxitin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cefoxitin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cefoxitin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA065214). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Cefoxitin And Dextrose In Duplex Container

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2030

Q3 2031

Trials by Indication[1]

Antibiotic1 trial

Major Abdominal Surgery1 trial

Abscess1 trial

Urinary Tract Infection1 trial

Surgical Site Infections1 trial

Cystic Fibrosis1 trial

Antibiotic Prophylaxis1 trial

Pyelonephritis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News